Drugs / TAB014
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03675880 | Jun 2018 → Feb 2019 | — | Lee's Pharmaceutical Limited | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05461339 | Jun 2022 → Sep 2024 overdue | wet macular degeneration | BioDlink Biopharm Co., Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAB014 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03675880 ↗ |
| Modality | Monoclonal antibody | “TAB014 Monoclonal Antibody Injection” NCT03675880 ↗ |
| Route | Intravitreal | “Subjects will receive intravitreal injections of TAB014 Monoclonal Antibody Injection in one eye” NCT03675880 ↗ |